Related Experiment Video
Updated: Apr 17, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
12.0K
Aggregates in apheresis-derived platelet concentrates: A 5-year single-centre experience
Matea Vinković1,2, Ana Hećimović3, Irena Jukić2,3
1Research and Development Department, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
Vox Sanguinis
|April 17, 2024
Summary
Persistent aggregates in apheresis-derived platelet concentrates (APCs) lead to higher discard rates. While apheresis technology influences initial visible aggregates (IVA), donor factors may contribute to persistent aggregates (PA) in APCs.
Area of Science:
- Transfusion Medicine
- Hematology
- Blood Component Processing
Background:
- Visible aggregates (IVA) in apheresis-derived platelet concentrates (APCs) often resolve within 24 hours.
- Persistent aggregates (PA) remain throughout the shelf life, impacting platelet concentrate quality.
- Factors influencing aggregate formation in APCs require further elucidation.
Purpose of the Study:
- To identify factors contributing to the occurrence of visible aggregates (IVA) and persistent aggregates (PA) in APCs.
- To analyze APCs discarded due to PA, comparing two apheresis technologies.
- To compare APCs with PA to a control group.
Main Methods:
- Cross-sectional study conducted from 2018-2022.
- Collected data on APCs exhibiting IVA.
- Analyzed APCs discarded due to PA, stratified by apheresis technology (Amicus and Haemonetics), and compared to controls.
Main Results:
- APCs with IVA had significantly higher discard rates compared to controls.
- 205 APCs (1.27% of total) were discarded due to PA.
- Amicus APCs with PA showed lower platelet counts and mean platelet volume, with less anticoagulant used. Haemonetics APCs with PA had higher platelet counts.
- No donor-related factors were found to predict PA.
Conclusions:
- APCs with IVA are frequently discarded due to aggregate issues and other quality parameter impairments.
- Apheresis technology, a known risk factor for IVA, was not confirmed as the primary risk factor for PA.
- Donor-related factors appear to play a role in the development of persistent aggregates in APCs.
Related Concept Videos
01:18Structure and Function of Platelets
6.8K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.8K
01:22Formation of the Platelet Plug
11.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
11.0K